OnDemand: September 2025 Grand Rounds - Pediatric Obesity: Current Obesity Medication Options and a Vission for the Future-Pediatric Obesity

Video Transcription

Video Summary

Dr. Bomberg, a pediatric obesity specialist, reviewed current and emerging medication options for treating obesity in children and adolescents, along with major real-world barriers and future directions in precision medicine. He explained how pediatric obesity is classified using BMI growth charts and noted that, in adolescents, four FDA-approved anti-obesity medications are currently available: orlistat, liraglutide, phentermine/topiramate, and semaglutide. Among these, GLP-1–based therapies such as semaglutide generally produce the greatest weight loss, while phentermine/topiramate is the most effective non-GLP-1 option. He also highlighted special-indication drugs such as setmelanotide for rare genetic obesity syndromes and diazoxide choline for hyperphagia in Prader-Willi syndrome.<br /><br />He reviewed recent guidelines, including the AAP recommendation to offer medication to youth 12 and older, and discussed the Lancet Commission’s distinction between “preclinical” and “clinical” obesity, while raising concerns about waiting for complications to appear in children.<br /><br />A major focus was access: insurance denials, lack of Medicaid coverage, high out-of-pocket costs, and the controversial role of compounded GLP-1 products. He emphasized that even the best treatments are ineffective if patients cannot obtain them.<br /><br />Looking ahead, he described pediatric trials of liraglutide in younger children, semaglutide down to age 6, and tirzepatide in adolescents, as well as several promising adult pipeline drugs.<br /><br />Finally, he discussed precision medicine approaches, including obesity phenotypes, genetic risk scores, and pharmacokinetic/pharmacodynamic dosing strategies, with the goal of matching the right treatment to the right patient at the right time.

Keywords

pediatric obesity

adolescent obesity

BMI growth charts

GLP-1 therapies

semaglutide

phentermine/topiramate

setmelanotide

Prader-Willi syndrome

precision medicine

insurance barriers